Axsome v. Alkem: Sunosi Solriamfetol ANDA Dispute Consolidated Into Multi-Defendant NJ Action
Axsome Malta Ltd. and Axsome Therapeutics, Inc. sued Alkem Laboratories Ltd. in the District of New Jersey, asserting five Orange Book-listed patents covering their Sunosi (solriamfetol) wakefulness drug. The standalone action lasted just 47 days before being consolidated into a broader multi-defendant ANDA litigation already involving Aurobindo, Hetero, and Hikma.
A rapid consolidation in a crowded Orange Book ANDA battle over Sunosi
On August 8, 2024, Axsome Malta Ltd. and Axsome Therapeutics, Inc. filed Civil Action No. 2:24-cv-08365 in the U.S. District Court for the District of New Jersey against Alkem Laboratories Ltd., asserting infringement of five Orange Book-listed patents covering their Sunosi (solriamfetol) product — a dopamine and norepinephrine reuptake inhibitor indicated for excessive daytime sleepiness. The five asserted patents are US11986455B2, US11998639B2, US11986454B1, US12005036B1, and US11969404B2.
The case was terminated after just 47 days, on September 24, 2024, when it was consolidated into the pre-existing Main Action No. 23-20354. That consolidation was jointly requested by Axsome and the defendants and followed a broader court-managed effort to unify related Sunosi ANDA cases filed against multiple generic challengers — including Aurobindo, Hetero, and Hikma — into a single proceeding. No merits ruling, claim construction, or injunction was issued in this docket.
The 47-day lifespan of this case is consistent with the administrative mechanics of ANDA litigation, where plaintiffs often file separate actions on newly-listed Orange Book patents and subsequently consolidate them to streamline discovery and trial. The speed of consolidation suggests both parties anticipated this outcome from the outset. What remains unresolved — and now continues in the Main Action — is whether Alkem’s proposed generic solriamfetol tablets infringe any of the five asserted patents and whether those patents are valid.
Filing to Case Consolidated in 47 days
47 days — resolved to consolidation faster than the median ANDA district court case
Case consolidated: what the transfer to the Main Action means for both parties
Consolidation is procedural, not a win or loss on the merits
When a court consolidates related cases, it merges them into a single proceeding for efficiency — typically sharing discovery, claim construction, and trial. No infringement finding, validity ruling, or injunction issued here. The substantive dispute over whether Alkem’s generic solriamfetol infringes Axsome’s five Orange Book patents continues in Main Action No. 23-20354, alongside claims against Aurobindo, Hetero, and Hikma.
No merits adjudicationAxsome retains full enforceability; claims proceed in unified action
Consolidation preserves all of Axsome’s asserted claims. By unifying multiple ANDA defendants in one proceeding, Axsome can pursue consistent claim construction and avoid conflicting rulings across dockets. The five Orange Book-listed patents remain in force and continue to support a 30-month stay of FDA approval for Alkem’s generic, provided the filing was timely. No rights were conceded in this docket.
Patents remain in forceAlkem now litigates alongside other generic challengers
Alkem’s defense of its ANDA application continues in the Main Action. Consolidation may benefit Alkem by allowing it to share litigation costs and coordinate invalidity arguments with co-defendants Aurobindo, Hetero, and Hikma. However, it also means any unfavorable ruling on claim construction or validity could bind all defendants simultaneously. Alkem has made no admission of infringement in this docket.
Defense continues — Main ActionMulti-defendant ANDA consolidation raises generic market entry risk
With at least four generic challengers — Alkem, Aurobindo, Hetero, and Hikma — now litigating against five Sunosi patents in a single NJ proceeding, the outcome of the Main Action will have broad commercial consequences. A plaintiff victory could delay generic solriamfetol entry for all defendants simultaneously. Conversely, a successful invalidity challenge by any defendant could open the market for all ANDA filers, consistent with Hatch-Waxman first-filer dynamics.
Multi-defendant market entry riskFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Axsome Malta, Ltd. | Company | Pharmaceutical patent holder — holder of US11986455B2 and four further solriamfetol patentsSearch in Eureka ↗ |
| Co-Plaintiff | Axsome Therapeutics, Inc. | Company | Search in Eureka ↗ |
| Defendant | Alkem Laboratories, Ltd. | Company | Generic pharmaceutical manufacturer seeking ANDA approval for solriamfetol oral tabletsSearch in Eureka ↗ |
| Plaintiff counsel | Alexander Lee Callo | Attorney | Counsel for Axsome Malta, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Charles Michael Lizza | Attorney | Counsel for Axsome Malta, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Sarah Ann Sullvian | Attorney | Counsel for Axsome Malta, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | William C. Baton | Attorney | Counsel for Axsome Malta, Ltd.Search in Eureka ↗ |
| Plaintiff law firm | Saul Ewing LLP | Law Firm | Representing Axsome Malta, Ltd.Search in Eureka ↗ |
| Defendant counsel | Rebekah R. Conroy | Attorney | Counsel for Alkem Laboratories, Ltd.Search in Eureka ↗ |
| Defendant law firm | Stone Conroy LLC | Law Firm | Representing Alkem Laboratories, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consolidation order reflects a jointly requested procedural alignment rather than any judicial finding on the merits. The language of the verdict recites the procedural history across at least eight related dockets, consistent with Axsome filing new actions each time additional Orange Book patents issued. The court’s consolidation into Main Action No. 23-20354 preserves judicial resources and standardises proceedings. Neither infringement nor validity was adjudicated in this docket; both issues survive into the consolidated action.
US11986455B2 and four Orange Book patents — solriamfetol (Sunosi) formulations
The five asserted patents — US11986455B2, US11998639B2, US11986454B1, US12005036B1, and US11969404B2 — are listed in the FDA Orange Book for Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor approved for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. Their application numbers suggest a continuation family, with filings concentrated in 2022–2023, consistent with life-cycle management of a commercially launched product.
Orange Book listing confers significant strategic value: it triggers Hatch-Waxman 30-month stays upon timely filing of infringement suits against ANDA applicants. With five patents listed and at least four generic challengers now consolidated in Main Action No. 23-20354, Axsome has constructed a patent thicket that requires generic entrants to mount comprehensive invalidity or non-infringement arguments on each patent. Any company developing or marketing solriamfetol generics — or related DNRI compounds — should closely monitor claim construction proceedings in the Main Action.
Should you run an FTO analysis against the Sunosi Orange Book patents?
Any company developing a generic, reformulated, or follow-on DNRI product in the solriamfetol space — or filing an ANDA referencing Sunosi — should conduct a freedom-to-operate analysis against all five asserted patents. The continuation family structure means claim scope may differ materially across related patents, and a product cleared under one patent may still infringe another. R&D teams exploring alternative solriamfetol dosage forms or delivery routes face particular exposure.
PatSnap Eureka’s FTO Search Agent can map the claim scope of each of the five Orange Book patents, identify prior art that informed their prosecution history, and flag related continuation applications that may not yet have published. For in-house IP teams monitoring the Main Action, Eureka’s litigation tracking tools provide real-time updates on Markman proceedings, claim construction orders, and any IPR petitions filed against this patent family.
Run a freedom-to-operate analysis on US11986455B2 to assess your product’s exposure
Run FTO in Eureka →Similar Orange Book ANDA patent cases in the District of New Jersey
Cases involving Orange Book-listed pharmaceutical patents and ANDA consolidation proceedings in the District of New Jersey, including solriamfetol and CNS drug formulation disputes.
What this case signals for the solriamfetol and CNS generics IP landscape
The rapid consolidation of multiple Sunosi ANDA cases signals an aggressive, portfolio-based Orange Book enforcement strategy by Axsome.
Orange Book stacking: Axsome’s five-patent enforcement posture raises the validity bar
Asserting five Orange Book-listed patents across a coordinated multi-defendant ANDA campaign is a well-established strategy to extend Hatch-Waxman exclusivity. Generic challengers must invalidate or design around each asserted patent. Companies monitoring solriamfetol generics should track claim construction in the Main Action — any narrow reading could create design-around space.
Consolidation efficiency cuts litigation cost but concentrates outcome risk
For both Axsome and the generic defendants, consolidation reduces duplicative discovery but means a single adverse ruling — whether on infringement or validity — affects all parties simultaneously. IP teams at companies with related CNS ANDA filings should monitor the Main Action’s scheduling order for key milestones including Markman hearing dates.
Axsome v Alkem — key questions answered
Civil Action No. 2:24-cv-08365 was filed by Axsome Malta Ltd. and Axsome Therapeutics, Inc. against Alkem Laboratories Ltd. on August 8, 2024, asserting five Orange Book patents covering Sunosi (solriamfetol). It was closed on September 24, 2024 — after just 47 days — when it was consolidated by joint request into Main Action No. 23-20354, the multi-defendant ANDA proceeding in the District of New Jersey. No merits ruling was issued.
Axsome asserted five Orange Book-listed patents: US11986455B2, US11998639B2, US11986454B1, US12005036B1, and US11969404B2. All five relate to solriamfetol (Sunosi) formulations or methods of use and are listed in the FDA’s Orange Book, triggering Hatch-Waxman protection against ANDA-based generic entry.
Consolidation means Alkem’s defense of its generic solriamfetol ANDA now proceeds within Main Action No. 23-20354 alongside co-defendants Aurobindo, Hetero, and Hikma. No infringement finding was made against Alkem in the standalone case. Consolidation is a procedural step that centralises discovery and potential trial, but does not determine the outcome on infringement or validity.
Solriamfetol is a dopamine and norepinephrine reuptake inhibitor (DNRI) approved under the brand name Sunosi for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea. As a commercially valuable branded product, it attracted multiple generic ANDA filings from companies including Alkem, Aurobindo, Hetero, and Hikma — each challenging Axsome’s Orange Book patent coverage through Paragraph IV certifications.
The consolidated Main Action No. 23-20354 in the District of New Jersey continues as of the close of this docket (September 24, 2024). Unichem was dismissed in June 2024 and Sandoz in September 2024. The remaining defendants — Alkem, Aurobindo, Hetero, and Hikma — are litigating Axsome’s five Orange Book solriamfetol patents in the unified proceeding. Markman and trial scheduling details are governed by the Main Action’s docket.
PatSnap Eureka searches patents and litigation data to answer instantly.